Zhongzhi Pharmaceutical (HKG:3737) expects a 45% year-over-year decline in net profit in 2024, a Friday bourse filing said.
The drugmaker attributed the anticipated drop in profit mainly to a lower gross profit margin and a rise in investment costs through online channels and offline advertising expenses.
Price (HKD): $1.01, Change: $-0.010, Percent Change: -0.98%